Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 337: | Line 337: | ||
! rowspan="3" align="center" style="background:#DCDCDC;" + |Marginal zone lymphoma | ! rowspan="3" align="center" style="background:#DCDCDC;" + |Marginal zone lymphoma | ||
! align="center" style="background:#DCDCDC;" + |Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type | ! align="center" style="background:#DCDCDC;" + |Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 468: | Line 468: | ||
| | | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]] | ! colspan="2" align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]] | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* Production of [[Cytokine|cytokines]], such as [[TNF alpha]] and IL-2R, provide important stimuli for [[malignant]] [[B cell|B cells]] proliferation in hairy cell leukemia. | * Production of [[Cytokine|cytokines]], such as [[TNF alpha]] and IL-2R, provide important stimuli for [[malignant]] [[B cell|B cells]] proliferation in hairy cell leukemia. | ||
** The ''p38-MAPK-JNK'' cascade | ** The ''p38-MAPK-JNK'' cascade | ||
** The ''MEK-ERK'' cascade | ** The ''MEK-ERK'' cascade | ||
** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade | ** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* [[Fever]] | * [[Fever]] | ||
* [[Night sweat|Night sweats]] | * [[Night sweat|Night sweats]] | ||
Line 486: | Line 486: | ||
* Recurrent [[Infection|infections]] | * Recurrent [[Infection|infections]] | ||
* Early satiety | * Early satiety | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* [[Pallor]], | * [[Pallor]], | ||
* [[Petechiae]] | * [[Petechiae]] | ||
* [[Splenomegaly]] | * [[Splenomegaly]] | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* Tartrate-resistant acid phosphatase | * Tartrate-resistant acid phosphatase positive | ||
* CBC | * CBC | ||
** Decreased [[hemoglobin]] concentration | ** Decreased [[hemoglobin]] concentration | ||
** Decreased [[platelets]] count | ** Decreased [[platelets]] count | ||
** | ** | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* [[Annexin A1]] | * [[Annexin A1]] | ||
* [[CD20]] | * [[CD20]] | ||
Line 515: | Line 515: | ||
* [[CD11c]] | * [[CD11c]] | ||
* [[FMC7]] | * [[FMC7]] | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* Small cells with "fried egg"-like appearance | |||
* Well-demarcated thread-like [[cytoplasmic]] extensions | |||
* Clear cytoplasm | |||
* Central round [[nucleus]] | |||
* Peri-nuclear clearing ("water-clear rim" appearance) | |||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| | | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor T-cell Lymphomas | * Precursor T-cell Lymphomas | ||
| align="center" style="background:#F5F5F5;" + | | |||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
|- | |- | ||
| | | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
|T cell lymphoma | |T cell lymphoma | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Cutaneous T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Cutaneous T-cell lymphoma | ||
! align="center" style="background:#DCDCDC;" + |[[Mycosis fungoides]] / [[Sézary syndrome]] | ! align="center" style="background:#DCDCDC;" + |[[Mycosis fungoides]] / [[Sézary syndrome]] | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7. | * The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7. | ||
* It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells. | * It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells. | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma | * [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma | ||
* Generalized [[itching]]([[pruritus]]) | * Generalized [[itching]]([[pruritus]]) | ||
Line 629: | Line 628: | ||
* [[Anemia]] | * [[Anemia]] | ||
* May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination) | * May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination) | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* Cutaneous manifestations | * Cutaneous manifestations | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
| | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| | | |
Revision as of 19:00, 7 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Category | Disease | Etiology | Mechanism | Clinical manifestations | Paraclinical findings | Gold standard | Associated findings | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | ||||||||||||||||||||||||||
Demography | History | Symptoms | Signs | CBC | PBS | PT/PTT | Immunochemistry | Histopathology | Other | |||||||||||||||||
Inherited | Acquired | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | LAP | Hepatosplenomegaly | Other | WBC | Hb | Plt | |||||||||||||
HL | ||||||||||||||||||||||||||
Hodgkin's Lymphoma | ||||||||||||||||||||||||||
NHL | ||||||||||||||||||||||||||
B Cell Lymphoma | Precursor B-cell lymphoblastic leukemia/lymphoma |
|
||||||||||||||||||||||||
Follicular lymphoma |
|
|
+ | + |
|
|
+ |
| ||||||||||||||||||
Mantle cell lymphoma |
|
|
Abdominal distention |
|
Generalized lymphadenopathy | + |
|
|
↓ | Nl to ↓ |
|
|
Elevated LDH | |||||||||||||
Diffuse large B cell lymphoma |
|
|
|
↓ | ↓ | Nl to ↓ |
|
Centroblastic
Immunoblastic
Anaplastic
|
|
|||||||||||||||||
Category | Disease | Etiology | Inherited | Acquired | Demography | History | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | LAP | Hepatosplenomegaly | Other | WBC | Hb | Plt | PBS | PT/PTT | Immunochemistry | Histopathology | Other lab findings | Gold standard | Associated findings | |
Burkitt lymphoma |
|
|
|
|
|
|||||||||||||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
|||||||||||||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
||||||||||||||||||||||||
Splenic marginal zone lymphoma |
|
|
||||||||||||||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
|
| ||||||||||||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
|||||||||||||||||||||||||
Hairy cell leukemia |
|
|
|
|||||||||||||||||||||||
Precursor T-cell lymphoblastic leukemia/lymphoma |
|
|||||||||||||||||||||||||
Adult T cell leukemia/lymphoma | ||||||||||||||||||||||||||
T cell lymphoma | Anaplastic large cell lymphoma | |||||||||||||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
||||||||||||||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma | |||||||||||||||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma | ||||||||||||||||||||||||||
Enteropathy-type intestinal T-cell lymphoma | ||||||||||||||||||||||||||
Extranodal T-cell lymphoma, nasal type | ||||||||||||||||||||||||||
Angioimmunoblastic T-cell lymphoma | ||||||||||||||||||||||||||
Peripheral T-cell lymphoma, unspecified |